Reports of Practical Oncology and Radiotherapy最新文献

{"title":"Diffuse midline gliomas, H3K27M-altered, of the pineal gland: the first synaptophysin-positive case and a systematic review.","authors":"Gabriele Gaggero, Marco Pavanello, Claudia Milanaccio, Antonia Ramaglia, Chiara Trambaiolo Antonelli, Maria Sole Venanzi, Antonio Verrico, Martina Resaz, Valerio Gaetano Vellone","doi":"10.5603/rpor.108660","DOIUrl":"10.5603/rpor.108660","url":null,"abstract":"<p><p>Diffuse midline gliomas (DMGs) with H3K27M alterations are rare, aggressive, World Health Organization (WHO) grade 4 tumors arising in midline central nervous system (CNS) structures, characterized by a lysine-to-methionine substitution at histone H3K27, which disrupts epigenetic regulation via global loss of H3K27 trimethylation. The pineal gland is an exceptionally uncommon site of origin. We report the first case of a synaptophysin-positive, H3K27M-altered DMG in the pineal gland of a 7-year-old female, characterized by hypercellularity, moderate atypia, high mitotic activity, and a Ki-67 index of 30%. Immunohistochemistry confirmed positivity for glial markers: glial fibrillary acidic protein (GFAP), oligodendrocyte transcription factor 2 (Olig2), loss of hypotrimethylation of lysine 27 on histone H3 (H3K27me3), and synaptophysin expression, an unusual feature for DMGs. Methylation profiling established the diagnosis. A systematic review identified seven cases of pineal H3K27M-altered DMG (age ranged from 7 to 65 years, with three pediatric and four adult) revealing notable immunohistochemical heterogeneity, limited molecular data (only our case had available methylation profiling) and a synaptophysin expression limited to our pediatric case. Sparse clinical outcome data precluded robust prognostic comparisons. These findings underscore the biological heterogeneity and diagnostic challenges of pineal DMGs and underscore the necessity of comprehensive molecular and immunohistochemical assessments to optimize diagnosis and guide emerging targeted therapies.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"840-849"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implementation of a hybrid solitary dynamic portal radiotherapy for left-sided post-mastectomy chest-wall and regional nodal irradiation using Monaco TPS.","authors":"K Mohamathu Rafic, Md Akhtaruzzaman, U E Martin, S K Mounageetha, K Harish Kumar, Sajjad Yousuf, Simon Pavamani","doi":"10.5603/rpor.109516","DOIUrl":"10.5603/rpor.109516","url":null,"abstract":"<p><strong>Background: </strong>A hybrid solitary dynamic portal radiotherapy (h-SDPRT) technique for complex chest-wall and regional nodal irradiation was clinically implemented on the Monaco treatment planning system (TPS) by effectively adapting the Eclipse-based h-SDPRT method with minimal amendments to align with Monaco-specific technical constraints while maintaining consistent and reproducible dosimetric outcomes.</p><p><strong>Materials and methods: </strong>This technique was evaluated on ten left-sided post-mastectomy radiotherapy (PMRT) patients, delivering 80-85% of the prescribed dose through asymmetric static open field apertures with the Elekta Agility multileaf collimator (MLC), and the remaining 15-20% via a unidirectional solitary dynamic field with differential blocks, composed of 10-15 MLC control points (4-5% of the dose per segment).</p><p><strong>Results: </strong>The h-SDPRT plans demonstrated excellent dose coverage to the chest-wall target (D₉₉ ≥ 96.3 ± 0.2%) and regional nodes (D₉₉ ≥ 96.4 ± 0.8%), optimal conformity (1.5 ± 0.1), and superior homogeneity (0.104 ± 0.01), while effectively sparing critical organs-at-risk (OAR) viz., ipsilateral lung (V₂₀ ≤ 26.7 ± 2.0% and D_mean: 14.3 ± 5.7 Gy) and heart (V₂₅ ≤ 6.4 ± 3.8% and D_mean: 6.1 ± 1.6 Gy), with complete sparing of contralateral lung (V₅ ≤ 0.1 ± 0.2% and D_mean: 1.3 ± 0.3 Gy) and breast (V₅ ≤ 1.5 ± 1.0% and D_mean: 1.6 ± 0.2 Gy). Gamma evaluation (γ) showed > 95% pixels passing the standard 3% dose difference and 3 mm distance-to-agreement γ criteria, with results closely aligning with Eclipse TPS data.</p><p><strong>Conclusions: </strong>The h-SDPRT technique minimizes the risk of \"geometrical miss\" and reduces delivery uncertainties associated with irregular or thin chest-wall with comprehensive nodal irradiation. By combining dominant static portals with simplified unidirectional dynamic field sequencing strategy, this approach provides a feasible and effective solution for PMRT.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"758-766"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evaluation of serum magnesium and calcium/magnesium ratio in patients with breast cancer receiving adjuvant chemotherapy.","authors":"Joanna Grupińska, Witold Kycler, Dominik Dzieniszewski, Elżbieta Kaja, Agata Kubicka, Bogna Gryszczyńska, Jacek J Brzeziński, Maria Iskra, Dorota Formanowicz, Natalia Idaszewska, Ewa Leporowska, Magdalena Budzyń","doi":"10.5603/rpor.108613","DOIUrl":"10.5603/rpor.108613","url":null,"abstract":"<p><strong>Background: </strong>Magnesium (Mg) deficiency may promote tumor growth and metastasis, hence the need to monitor and possibly normalize its level during treatment is emphasized. Therefore, our study aimed to assess the effect of a six-week adjuvant chemotherapy on serum Mg and calcium (Ca)/Mg ratio in patients with breast cancer.</p><p><strong>Materials and methods: </strong>The study included a group of 80 women with breast cancer who were qualified for adjuvant chemotherapy in the AC regimen (doxorubicin and cyclophosphamide). Serum magnesium and calcium levels were determined spectrophotometrically. Serum high-sensitivity C-reactive protein (hs-CRP) was measured using enzyme-linked immunosorbent assay (ELISA).</p><p><strong>Results: </strong>In the postoperative period, decreased serum magnesium and increased Ca/Mg ratio were observed in breast cancer women compared to healthy controls. After six weeks of AC chemotherapy, magnesium levels increased significantly, reaching a lower reference value. The same trend was noticed for the Ca/Mg ratio, which increased slightly but remained higher than in the control group. In patients with higher values of hs-CRP after treatment, decreased serum magnesium level was observed.</p><p><strong>Conclusions: </strong>Our study showed that the postoperative period is associated with magnesium deficiency in breast cancer patients. However, AC chemotherapy tends to normalize its concentration. During treatment, low magnesium concentration was associated with increased hs-CRP levels. This finding confirms that magnesium deficiency may induce inflammation, which has been implicated in tumor growth and metastasis. However, further research is needed to explain the role of magnesium in tumor development clearly.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"816-827"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can superficial parotid sparing alone impact xerostomia in head and neck cancer? A retrospective study correlating the type of tobacco use, chronic xerostomia, and parotid sparing.","authors":"Nikunj Patil, Sachi Chauhan, Sidharth Satish Menon, Umesh Velu, Anshul Singh, Krishna Sharan, Shirley Lewis","doi":"10.5603/rpor.108673","DOIUrl":"10.5603/rpor.108673","url":null,"abstract":"<p><strong>Background: </strong>Head and neck cancer is one of the most common cancers in India, with tobacco chewing being the predominant form of tobacco consumption. We aimed to assess the impact of superficial gland sparing on xerostomia.</p><p><strong>Materials and methods: </strong>Patients with histopathological diagnosis of head and neck cancer treated with curative intent radiotherapy with intensity-modulated radiotherapy (IMRT) to a dose of 60-70 Gy in 30-35 fractions with or without chemotherapy from June 2017 to March 2020 were included in the study. The superficial and deep lobes of the parotid were contoured retrospectively. The physician-reported Radiation Therapy Oncology Group (RTOG) xerostomia toxicity grades at two years were retrieved from records.</p><p><strong>Results: </strong>One hundred seventy-four patients were included in the study. Tobacco chewing was the most common form of use, followed by smoking. Tobacco chewers had significantly smaller mean parotid (53cc <i>vs</i>. 60cc, p = 0.02) and mean submandibular gland volumes (6 cc <i>vs</i>. 14 cc, p < 0.001) as compared to smokers. Bilateral or contralateral parotid sparing (mean dose < 26 Gy) was achieved in 62.7%, bilateral or contralateral superficial lobe in 27.6% and no sparing in 9.8% of patients. The xerostomia was similar in smokers and chewers (p = 0.95). Patients with bilateral or contralateral superficial lobe sparing had lower grade II/III xerostomia rates than the no-sparing group (p = 0.038).</p><p><strong>Conclusions: </strong>Tobacco chewers have smaller volumes of salivary glands. Contralateral or bilateral superficial parotid sparing translated into better xerostomia scores at two years.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"789-795"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing the synergy of contact brachytherapy and immune checkpoint inhibitors in advanced melanoma: first reported case series.","authors":"Artur Jan Chyrek, Łukasz Galus, Jacek Mackiewicz, Adam Kluska, Wojciech Maria Burchardt, Adam Chicheł","doi":"10.5603/rpor.108661","DOIUrl":"10.5603/rpor.108661","url":null,"abstract":"<p><strong>Background: </strong>Melanoma is an aggressive malignancy with high metastatic potential, often requiring systemic treatment with immune checkpoint inhibitors (CHI) in advanced stages. While CHI has significantly improved outcomes, its combination with local radiotherapy - particularly brachytherapy (BT) - may further enhance therapeutic efficacy by promoting immunogenic tumor cell death. BT enables precise delivery of high radiation doses, providing rapid symptom relief and potentially triggering local and systemic immune responses. This case series presents the first known clinical experience with noninvasive contact high-dose-rate brachytherapy (HDR-BT) combined with CHI in patients with metastatic melanoma treated in a palliative setting.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed four patients with stage IV melanoma and symptomatic subcutaneous metastases, all receiving ongoing CHI (nivolumab or pembrolizumab). Each underwent a single HDR-BT session (5-7 Gy) using a Freiburg Flap applicator. The primary goal was symptom relief. Treatment response was assessed clinically and radiologically, focusing on local control, response of non-irradiated lesions, progression-free survival (PFS), and overall survival (OS).</p><p><strong>Results: </strong>All patients experienced rapid clinical improvement and significant regression of the irradiated lesion, with minimal (Grade 0-1) acute skin toxicity. In two cases, complete remission of treated sites was achieved. One patient demonstrated long-term remission in both subcutaneous and visceral metastases. Median PFS was 3.4 months (range: 1.5-15.0), and OS ranged from 8.5 to 22 months.</p><p><strong>Conclusions: </strong>Single-fraction contact HDR-BT in combination with CHI appears to be a safe and effective palliative strategy for metastatic melanoma, offering fast local control, minimal toxicity, and potential systemic immune benefits.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"773-780"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategic cancer therapy planning: optimizing treatment and quality of life with Markov decision processes.","authors":"Seema Singh, Chandrahas Sahu, Pushpendra Singh, Alka Mishra, Santosh Kumar Mishra, Pawan Kumar Patnaik","doi":"10.5603/rpor.108580","DOIUrl":"10.5603/rpor.108580","url":null,"abstract":"<p><strong>Background: </strong>In managing the progression of diseases, particularly cancer, Markov decision processes (MDP) and dynamic therapy regimes are gaining prominence. Despite this, cancer treatments often negatively impact patients' quality of life, leading many to abandon effective, accessible, and affordable therapies.</p><p><strong>Materials and methods: </strong>This paper introduces a novel MDP-based mathematical framework for optimizing multi-therapy treatment schedules in malignancy therapy. Through practical illustrations, we demonstrate the utility and applicability of the proposed framework. Our approach integrates both patient utility and the physician's net benefit function, accounting for treatment options and survival probabilities across diverse clinical profiles. The system state in our MDP model is defined by tumor progression and normal tissue side effects, while the response field encompasses treatment outcomes categorized into recurrence, tumor regression, and healthy tissue safety. At each decision stage, the physician assesses the patient's condition and selects the optimal treatment strategy to maximize the final reward, determined by the patient's health at the end state.</p><p><strong>Results/conclusions: </strong>This framework offers a holistic approach to improving overall treatment outcomes while recognizing the importance of preserving patients' quality of life.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"735-748"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical governance in radiation oncology.","authors":"Julian Malicki, Ferran Guedea, Marco Krengli","doi":"10.5603/rpor.110118","DOIUrl":"10.5603/rpor.110118","url":null,"abstract":"<p><p>Clinical governance (CG) is an emerging framework that ensures accountability for delivering safe, effective, and continuously improving healthcare services. Originally introduced in the United Kingdom in the late 1990s as part of reforms in the National Health Service, CG draws upon principles of corporate governance to establish system-wide oversight of clinical quality, safety, and accountability. CG provides an overarching organisational framework encompassing leadership structures, clinical effectiveness, risk management, audits, professional development, and patient engagement. In radiation oncology, CG plays a critical role in enhancing treatment safety and quality by standardising protocols, conducting regular audits and peer reviews, implementing risk management strategies, and supporting continuous education for multidisciplinary teams. It also ensures accountability through transparent reporting to regulators, collaboration with patient groups, and commitment to evidence-based practice. Ethical principles - beneficence, non-maleficence, autonomy, and justice - are central to CG and provide the foundation for maintaining professional standards of care. Despite the increasing use of the term clinical governance, it is often only poorly understood. In the present review, we define the concept of clinical governance and discuss its role in healthcare, with a particular focus on the field of radiation oncology.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"850-856"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of upper versus lower extremity rhabdomyosarcoma survival: A SEER database analysis.","authors":"Connor J Tupper, Laura M Cogua, Harvey Y Wang, Peter T Silberstein","doi":"10.5603/rpor.108577","DOIUrl":"10.5603/rpor.108577","url":null,"abstract":"<p><strong>Background: </strong>Rhabdomyosarcoma (RMS) of the extremities has a particularly poor prognosis compared to other primary sites due to an increased rate of alveolar histology, higher rate of metastasis, and the extent of regional lymph node involvement. To date there are few assessments comparing upper extremity (UE) to lower extremity (LE) RMS of the extremities using population-based registry, so we sought to compare survival between UE and LE RMS.</p><p><strong>Materials and methods: </strong>Using the Surveillance, Epidemiology, and End Results (SEER) database, cases of RMS of the UE and LE diagnosed between 2000-2020 were collected. Descriptive statistics and chi-square analyses were completed for one-and five-year survival. Log-rank and Cox regression analyses were completed to compare UE versus LE survival.</p><p><strong>Results: </strong>A total of 641 cases were included, of which 221 (34.5%) were UE and 420 (65.5%) were LE. On log-rank tests, UE survival was longer than LE survival (p = 0.021). The one-year survival rate was greater for the UE (88.7%) compared to the LE (81.4%) (p = 0.020) but similar at five-years. Cox regression analysis showed no difference in survival between UE and LE primary site (hazard ratio = 1.172, p = 0.322).</p><p><strong>Conclusions: </strong>In comparing UE and LE RMS survival, UE survival was greater at one-year, but not on adjusted analyses. These findings contribute to the few prior assessments of outcomes between UE and LE RMS, though direct comparisons between UE and LE should be included in future prospective studies.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"796-803"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptome-based model for predicting radiotherapy response in HNSCC patients.","authors":"Tomasz Kolenda, Piotr Białas, Alicja Braska, Kacper Guglas, Paulina Poter, Marlena Janiczek-Polewska, Anna Malicka-Durczak, Dominika Połczyńska-Hałas, Małgorzata Nowak, Patrycja Mantaj, Anna Zapłata, Ewa Leporowska, Zefiryn Cybulski, Anna Przybyła, Urszula Kazimierczak, Joanna Kaźmierska, Anna Teresiak","doi":"10.5603/rpor.109846","DOIUrl":"10.5603/rpor.109846","url":null,"abstract":"<p><strong>Background: </strong>The main treatment method for head and neck squamous cell carcinomas (HNSCCs) is surgery in combination with radiotherapy or chemoradiation. However, the tumor heterogeneity and tumor microenvironment are issues of radiotherapy success. Due to this fact, the radioresistance process is not fully understood and seems to be a challenge for current oncology.</p><p><strong>Materials and methods: </strong>Radiotherapy treated HNSCC patients were divided into two groups based on the overall survival and excluding those with human papillomavirus (HPV) infection or treated with chemotherapy or targeted therapy. Next, groups were compared based on the clinical-pathological and transcriptome data (RNAseq) from The Cancer Genome Atlas Project (TCGA) using Gene Set Enrichment Analysis (GSEA) software and GraphPad Prism toll.</p><p><strong>Results: </strong>A model was created, consisting of two contrasting groups of patients: effective treatment group (ETG, n = 34) and ineffective treatment group (ITG, n = 31) for radiotherapy. Patients in the ITG group had a significantly shorter progression-free interval (PFI) than the ETG group, with a median of 266 days (p < 0.0001). Between the ETG and ITG groups, no differences (p > 0.05) were observed in clinical and pathological parameters, except perineural invasion (p = 0.0068) and the presence of a new tumor event after initial treatment (p < 0.0001). Molecular pathway analysis showed that ITG patients had statistically significantly increased expression of genes associated with DNA repair.</p><p><strong>Conclusions: </strong>We observed that our model, consisting of two groups, differed at the molecular level in genetic changes. Moreover, the presented model and its characterization showed that it was potentially useful for searching for potential biomarkers.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"804-815"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain-heart: first case report of simultaneous toxicity of 5-fluorouracil.","authors":"Vladimir Ernesto Ullauri Solórzano, Emilio Patricio Abad Herrera, Diego Javier Páez Granda, Diana Victoria Moreira-Vera, Tannia Estefanía Aguirre Soria, Liliana Elizabeth Flores Rodríguez","doi":"10.5603/rpor.108579","DOIUrl":"10.5603/rpor.108579","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 6","pages":"863-865"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}